GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0

作者：

Phillips, Tycel ^{[1
]}

Matasar, Matthew ^{[2
]}

Eyre, Toby A. ^{[3
]}

Gine, Eva ^{[4
]}

de L'Etang, Audrey Filezac ^{[5
]}

Byrne, Ben ^{[6
]}

Lundberg, Linda ^{[5
]}

Padovani, Alejandra ^{[5
]}

Boetsch, Christophe ^{[5
]}

Bottos, Alessia ^{[5
]}

Qayum, Naseer ^{[6
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[3] Oxford Univ Hosp NHS Trust, Oxford, England

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] Roche Prod Ltd, Welwyn Garden City, Herts, England

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MCL; clinical trials; non-Hodgkin lymphoma; bispecific antibody therapy; adverse events; mantle cell lymphoma; phase; 3;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-339

引用

页码：S515 / S515

页数：1

共 50 条

[1] GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phillips, Tycel J.
Matasar, Matthew
Eyre, Toby A.
Gine, Eva
De L'Etang, Audrey Filezac
Byrne, Ben
Lundberg, Linda
Padovani, Alejandra
Boetsch, Christophe
Bottos, Alessia
Qayum, Naseer
BLOOD, 2023, 142
[2] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
BLOOD, 2019, 134
[3] Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
BLOOD, 2020, 136
[4] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Martin, Peter
Goy, Andre
Ramchandren, Radhakrishnan
Ferrante, Lucille
Londhe, Anil
McGowan, Tracy
Bartlett, Nancy L.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
[5] The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
Fischer, Luca
Jiang, Linmiao
Duerig, Jan
Schmidt, Christian
Stilgenbauer, Stephan
Bouabdallah, Krimo
Solal-Celigny, Philippe
Scholz, Christian W.
Feugier, Pierre
de Wit, Maike
Trappe, Ralf Ulrich
Hallek, Michael
Graeven, Ullrich
Haenel, Mathias
Hoffmann, Martin
Delwail, Vincent
Macro, Margaret
Greiner, Jochen
Giagounidis, Aristoteles A. N.
Dargel, Beate
Durot, Eric
Foussard, Charles
Silkenstedt, Elisabeth
Weigert, Oliver
Pott, Christiane
Klapper, Wolfram
Hiddemann, Wolfgang
Unterhalt, Michael
Hoster, Eva
Ribrag, Vincent
Dreyling, Martin
LEUKEMIA, 2024, 38 (06) : 1307 - 1314
[6] AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
Sasse, Stephanie
Momotow, Jesko
Plutschow, Annette
Huttmann, Andreas
Basara, Nadezda
Koenecke, Christian
Martin, Sonja
Bentz, Martin
Grosse-Thie, Christina
Thorspecken, Sven
de Wit, Maike
Kobe, Carsten
Dietlein, Markus
von Tresckow, Bastian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
BLOOD, 2020, 136
[7] AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial
Momotow, J.
Sasse, S.
Pluetschow, A.
Huettmann, A.
Basara, N.
Koenecke, C.
Martin, S.
Bentz, M.
Grosse-Thie, C.
Thorspecken, S.
de Wit, M.
Kobe, C.
Dietlein, M.
von Tresckow, B.
Fuchs, M.
Borchmann, P.
Engert, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 89 - 89
[8] Multicenter, open-label trial of PXD 101 in patients with relapsed/refractory peripheral T-cell lymphoma
Zain, J. M.
O'Connor, O.
Zinzani, P. L.
Norman, A.
Brown, P. de Nully
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[9] Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial
Furtado, Michelle
Dyer, Martin J. S.
Johnson, Rod
Berrow, Margie
Rule, Simon
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 575 - 578
[10] AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Sasse, Stephanie
Brockelmann, Paul Jan
Momotow, Jesko
Plutschow, Annette
Huttmann, Andreas
Basara, Nadezda
Koenecke, Christian
Martin, Sonja
Bentz, Martin
Grosse-Thie, Christina
Thorspecken, Sven
de Wit, Maike
Kobe, Carsten
Dietlein, Markus
v Tresckow, Bastian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1871 - 1878

← 1 2 3 4 5 →